← Back

PFEPfizer

$28.00+1.82%Delayed market dataPharmaPharma & biotech · 16 peers →

What's moving this stock lately

1 direct · 1 2nd-order · 0 thematic

Ranked by relevance and recency.

#1Impact0.98%bearishDirectThese 6 High-Yield Dividends May Be Too Good to Be True15d ago
Post-pandemic revenue decline and patent-cliff pressure put the elevated dividend at risk of a potential cut, per the article
Impact chain →
Also named: BEN · WU · TROW · BXP · VNO · LYB
#2Impact0.46%bullish2nd-orderFDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults42d ago
As a Priovant JV partner and origin of the molecule, Pfizer holds indirect economic and commercial upside from the approval.
Impact chain →
Also named: ROIV · ARGX · OCGXY

🎯 Market expectations

Estimate coverage Medium · 45/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$0.77Estimate range $0.67 ~ $0.94 · 5 analysts

History: actual vs consensusavg +16.6%

Jun 2026$0.77 vs $0.68+13.24%
Mar 2026$0.75 vs $0.71+5.63%
Dec 2025$0.66 vs $0.57+15.79%
Sep 2025$0.87 vs $0.66+31.82%

The takeaway

Recent results have exceeded consensus by an average of +16.6%, which may have raised expectations for the next report.

Analyst estimates, not our forecast · not investment advice

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $62.6B · latest quarter up 2.6% YoY · profitable (FY net income $7.8B) · short activity within its normal range.

FY revenue

$62.6B

2025-12

Latest Q YoY

+2.6%

FY net income

$7.8B

Diluted EPS

$1.37

Short volume

46.5%

20d avg 44.5% · normal

🐋 5%+ ownership filings (last 180d)

The following investors reported beneficial ownership of more than 5% in recent SEC filings. "Activist" filers stated an intent to influence control of the company; "Passive" indicates the filer did not report such an intent.

2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC

🕰️ Price × news · analysis history

Drag to pan, scroll to zoom · real daily bars and volume

The 26 past analyses on this chart are Pro — price and volume only for now▂ volume

📜 Call history (newest first

Pro only

26 past analyses of this stock, each checked against what the price did afterwards · sign up to view

Start my free trial

Unlock the full analysisStart my free trial

Current conviction

Crowding

Risk temperature

Tail risk

Triggers

Money flow

Insider signals

Unlock the full analysis

See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.

Start my free trial